Your browser doesn't support javascript.
loading
Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.
Borrero-Palacios, A; Cebrián, A; Gómez Del Pulgar, M T; García-Carbonero, R; Garcia-Alfonso, P; Aranda, E; Elez, E; López-López, R; Cervantes, A; Valladares, M; Nadal, C; Viéitez, J M; Guillén-Ponce, C; Rodríguez, J; Hernández, I; García, J L; Vega-Bravo, R; Puime-Otin, A; Martínez-Useros, J; Del Puerto-Nevado, L; Rincón, R; Rodríguez-Remírez, M; Rojo, F; García-Foncillas, J.
Affiliation
  • Borrero-Palacios A; Translational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.
  • Cebrián A; Translational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain. arancha.cebrian@oncohealth.eu.
  • Gómez Del Pulgar MT; Translational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.
  • García-Carbonero R; Medical Oncology Department, Hospital Virgen del Rocío, Sevilla, Spain.
  • Garcia-Alfonso P; Medical Oncology Department, Hospital Gral. Univ. Gregorio Marañón, Madrid, Spain.
  • Aranda E; Medical Oncology Department, Hospital Universitario Reina Sofía, Córdoba, Spain.
  • Elez E; Medical Oncology Department, Hospital Vall d'Hebrón, Barcelona, Spain.
  • López-López R; Medical Oncology Department, Complexo Hospitalario Universitario Santiago de Compostela, Galicia, Spain.
  • Cervantes A; Medical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
  • Valladares M; Medical Oncology Department, Complejo Hospitalario Universitario A Coruña, Galicia, Spain.
  • Nadal C; Medical Oncology Department, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain.
  • Viéitez JM; Medical Oncology Department, Hospital Universitario Central de Asturias, Asturias, Spain.
  • Guillén-Ponce C; Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Rodríguez J; Medical Oncology Department, Clínica Universitaria de Navarra, Navarra, Spain.
  • Hernández I; Medical Oncology Department, Complejo Hospitalario de Navarra, Navarra, Spain.
  • García JL; Oncology, Medical Unit, Merck S.L, an affiliate of Merck KGaA, Darmstadt, Germany.
  • Vega-Bravo R; Anatomopathology Department, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.
  • Puime-Otin A; Anatomopathology Department, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.
  • Martínez-Useros J; Translational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.
  • Del Puerto-Nevado L; Translational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.
  • Rincón R; Translational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.
  • Rodríguez-Remírez M; Translational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.
  • Rojo F; Anatomopathology Department, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain.
  • García-Foncillas J; Translational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain. jesus.garciafoncillas@oncohealth.eu.
Sci Rep ; 9(1): 7706, 2019 May 17.
Article in En | MEDLINE | ID: mdl-31097738
ABSTRACT
A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies Language: En Journal: Sci Rep Year: 2019 Type: Article Affiliation country: Spain

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies Language: En Journal: Sci Rep Year: 2019 Type: Article Affiliation country: Spain